natgillin/translations-raw huggingface dataset:
After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline (see section 4.8).
Pri nekaterih bolnikih se po uvedbi protivirusnega zdravljenja vrednosti serumske ALT lahko povišajo, medtem ko se vrednosti serumske HBV DNA zmanjšajo (glejte poglavje 4.8).
After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline.
Po uvedbi protivirusne terapije lahko pri nekaterih bolnikih serumski nivo ALT naraste, medtem ko vrednost serumske HBV DNA upade.
After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline.
Po uvedbi protivirusnega zdravljenja lahko pri nekaterih bolnikih serumske ALT narastejo, medtem ko serumske vrednosti HBV DNA padejo.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10 % of peak after 4 hours and < 1 % of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1 % of peak prior to the second infusion of zoledronic acid on day 28.
Po začetku infuzije zoledronske kisline so se plazemske koncentracije zoledronske kisline hitro zvišale, dosegle ob koncu obdobja infuzije vrh, ki mu je sledilo hitro znižanje na < 10 % najvišje koncentracije po 4 urah in na < 1 % najvišje koncentracije po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki pred drugo infuzijo zoledronske kisline na 28. dan niso presegle 0,1 % maksimalne koncentracije.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Po začetku infundiranja zoledronske kisline se je njena koncentracija v plazmi zelo hitro zvišala, dosegla vrh ob koncu infundiranja, nato je sledilo hitro zmanjšanje na < 10% najvišje koncentracije po 4 urah in na < 1% najvišje koncentracije po 24 urah; sledilo je dolgotrajno obdobje zelo nizke koncentracije, ki pred drugo infuzijo zoledronske kisline 28. dan ni presegla 0,1% najvišje koncentracije.
After initiating the infusion of zoledronic acid, the plasma concentrations of zoledronic acid rapidly increased, achieving their peak at the end of the infusion period, followed by a rapid decline to < 10% of peak after 4 hours and < 1% of peak after 24 hours, with a subsequent prolonged period of very low concentrations not exceeding 0.1% of peak prior to the second infusion of zoledronic acid on day 28.
Po začetku infuzije zoledronske kisline so se plazemske koncentracije zoledronske kisline hitro zvišale, dosegle ob koncu obdobja infuzije vrh, ki mu je sledilo hitro znižanje na < 10% najvišje koncentracije po 4 urah in na < 1% najvišje koncentracije po 24 urah, čemur je sledilo dolgotrajno obdobje zelo nizkih koncentracij, ki pred drugo infuzijo zoledronske kisline na 28. dan niso presegle 0,1% maksimalne koncentracije.
After initiation of therapy, your doctor will maintain your haemoglobin level between 10 and 12 g/dl
Zdravnik bo po uvedbi terapije ohranjal vašo raven hemoglobina med 10 in 12 g/dl.
After initiation, the recommended injection cycle of Xeplion is monthly.
Po uvajanju je priporočeno enkrat mesečno injiciranje zdravila Xeplion.
After injecting Humira, immediately throw away the used syringe in a special container as instructed by your doctor, nurse or pharmacist.
Po injiciranju zdravila Humira porabljeno brizgo takoj zavrzite v poseben vsebnik, kot vam je naročil zdravnik, medicinska sestra ali farmacevt.
After injecting the liquid, remove the needle and let go of your skin.
Ko ste tekočino vbrizgali, iglo izvlecite in spustite kožo.
After injecting the liquid, remove the needle while keeping the syringe at the same angle and maintaining pressure on the plunger, then let go of your skin.
Po injiciranju odstranite iglo, tako da jo držite pod enakim kotom in ohranjate pritisk na bat, nato pa spustite kožo.
After injecting the liquid, remove the needle while maintaining pressure on the plunger and then let go of your skin.
Ko ste raztopino vbrizgali, iglo izvlecite, medtem pa še vedno pritiskajte na bat, nato pa kožo izpustite.
After injecting Trudexa, immediately throw away the used syringe in a special container as instructed by your doctor, nurse or pharmacist.
Po injiciranju Trudexe porabljeno brizgo takoj zavrzite v poseben vsebnik, kot vam je naročil zdravnik, medicinska sestra ali farmacevt.
After injecting, use your thumb (or tip of your finger) to activate the pink safety cover by pushing the cover forward using the same hand until you hear and/or feel it click and lock into place over the needle.
Po injiciranju s palcem (ali konico kakšnega drugega prsta) aktivirajte rožnati varnostni pokrovček tako, da ga z isto roko potisnete naprej, dokler ne zaslišite in/ali začutite, da je kliknil in se je zaskočil nad iglo.
After injection any unused product must be discarded.
Po injiciranju je treba neporabljeno zdravilo zavreči.
After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.
Po injiciranju imunoglobulina lahko prehodno povečanje različnih pasivno prenesenih protiteles v bolnikovi krvi povzroči lažno pozitivne rezultate pri seroloških preiskavah.
After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results in serological testing.
Po injiciranju imunoglobulina lahko začasni porast različnih pasivno prenesenih protiteles v krvi bolnika povzroči lažno pozitivne rezultate seroloških preiskav.
After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results in serological testing.
Po injiciranju imunoglobulinov lahko prehodno zvišanje različnih pasivno prenesenih protiteles v bolnikovi krvi vodi v zavajajoče pozitivne rezultate serološkega testiranja.
After injection of Lymphoseek, external gamma detection imaging may be conducted.
Po injiciranju zdravila Lymphoseek lahko opravite zunanje slikanje z žarki gama.
After injection, do not recap the needle or detach it from the syringe.
Po injiciranju ne nameščajte pokrovčka na iglo in igle ne odstranjujte z brizge.
After injection, immediately apply a single-finger stroke to the activation assisted lever arm to activate the shielding mechanism (see Figure 5).
Takoj po injiciranju z enim prstom sprožite aktivacijsko asistirano ročico, da boste aktivirali mehanizem za zaščito (glejte sliko 5).
After injection, immediately throw away the used pen in a special container as instructed by your doctor, nurse or pharmacist.
Po injiciranju uporabljen peresnik zavrzite v poseben vsebnik, kot vam je naročil vaš zdravnik, medicinska sestra ali farmacevt.
After injection, immediately throw away the used syringe in a special container as instructed by your doctor, nurse or pharmacist.
Po injiciranju uporabljeno brizgo zavrzite v poseben vsebnik, kot vam je naročil vaš zdravnik, medicinska sestra ali farmacevt.
After injection, press the injection site with a small bandage or sterile gauze for several seconds.
Po injiciranju pritiskajte na mesto injiciranja več sekund z majhnim povojem ali sterilno gazo.
After injection, read the number shown in the Dose Feedback Window.
Po injiciranju preberite številko, prikazano v oknu za prikaz odmerka.
After injection, safely dispose of all unused NovoEight solution, the syringe with the infusion set, the vial with the vial adapter, and other waste materials as instructed by your pharmacist.
Po injiciranju varno zavrzite vso neporabljeno raztopino zdravila NovoEight, brizgo s kompletom za injiciranje, vialo z nastavkom viale in drug odpadni material, kot vam je naročil farmacevt.
After injection, safely dispose of all unused NovoEight solution, the syringe with the infusion set, the vial with the vial adapter, and other waste materials as instructed by your pharmacist.
Po injiciranju varno zavrzite vso neporabljeno raztopino zdravila NovoEight, brizgo s kompletom za injiciranje, vialo z nastavkom za vialo in drug odpadni material, kot vam je naročil farmacevt.
After injection, safely dispose of the syringe with the infusion set, the vial with the vial adapter, any unused NovoSeven and other waste materials as instructed by your doctor or nurse.
Po injiciranju varno zavrzite injekcijsko brizgo in komplet za injiciranje, vialo z nastavkom za vialo, vso neporabljeno zdravilo NovoSeven in drug odpadni material, kot vam je naročil vaš zdravnik ali medicinska sestra.
After injection, the microbubbles travel in the blood, where they reflect ultrasound waves more than the surrounding tissues.
Po injiciranju mikromehurčki potujejo po krvi, kjer odbijajo ultrazvočne valove bolj kot obdajajoča tkiva.
After injection: The injection has stopped but you can still see medicine in the cartridge, or the plunger in the cartridge has not completely moved forward.
Po injiciranju: Injiciranje se je ustavilo, a v vložku lahko še vedno vidite zdravilo, oziroma se bat v vložku ni popolnoma pomaknil naprej.
After inoculation, the virus expresses the protective protein, but does not replicate in the cat.
V Po inokulaciji virus izloča zaščitne proteine, a se v mački ne množi.
After intake of ellaOne, breastfeeding is not recommended for one week.
Po vnosu zdravila ellaOne se dojenje odsvetuje en teden.
After intravenous (IV) administration the volume of distribution at steady state (Vss) ranges from 1,200 to 1,400 L.
Po intravenski uporabi je porazdelitveni volumen v stanju dinamičnega ravnovesja (Vss) od 1200 do 1400 l.
After intravenous administration of 0.03 mmol/kg dose the mean half-life of the distribution phase (t1/2) was 0.48 ± 0.11 hours and the volume of distribution at steady state was 148 ± 16 ml/kg, roughly equivalent to that of extracellular fluid.
Po intravenski aplikaciji odmerka 0,03 mmol/kg je bila srednja vrednost razpolovnega časa porazdelitvene faze (t1/2) 0,48 ± 0,11 ure, volumen porazdelitve v stanju dinamičnega ravnovesja pa 148 ± 16 ml/kg, kar približno ustreza vrednosti zunajcelične tekočine.
After intravenous administration of [3H]-labelled glycopyrronium bromide to humans, the mean urinary excretion of radioactivity in 48 hours amounted to 85% of the dose.
Po intravenskem odmerjanju s [3H] označenega glikopironijevega bromida pri ljudeh se je v 48 urah v urinu izločilo povprečno 85 % radioaktivno označenega odmerka.
After intravenous administration of [3H]-labelled glycopyrronium bromide, the mean urinary excretion of radioactivity in 48 hours amounted to 85% of the dose.
Po intravenskem odmerjanju s [3H] označenega glikopironijevega bromida se je v 48 urah v urinu izločilo povprečno 85 % radioaktivno označenega odmerka.
After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours.
Po intravenski uporabi 1-miligramskega odmerka je razpolovni čas izločanja 4,5 ur.
After intravenous administration of agalsidase beta to adults with an infusion time of approximately 300 minutes and at a dose of 1 mg/kg body weight, biweekly, mean Cmax plasma concentrations ranged from 2000-3500 ng/ml, while the AUCinf ranged from 370-780 g min/ml.
Po intravenski aplikaciji agalzidaze beta pri odraslih s trajanjem infundiranja približno 300 minut in pri odmerku 1 mg/kg telesne mase na vsaka 2 tedna so bile srednje vrednosti Cmax plazemske koncentracije od 2.000 do 3.500 ng/ml, medtem ko je bila vrednost AUCinf od 370 do 780 µg min/ml.
After intravenous administration of palonosetron 0.25 mg once daily for 3 days in 12 healthy subjects, the mean ( SD) increase in plasma palonosetron concentration from Day 1 to Day 3 was 110  45 %.
Po intravenskem dajanju palonosetrona 12 zdravim osebam v odmerku 0,25 mg enkrat na dan 3 dni je koncentracija palonosetrona v plazmi od 1. do 3. dne povprečno ( SD) zrasla za 110  45 %.
After intravenous administration robenacoxib was rapidly cleared from blood (CL of 0.44 L/kg/h in cats and 0.81 L/kg/h in dogs) with an elimination t1/2 of 1.1 h in cats and 0.8 h in dogs.
Robenakoksib se po intravenozni aplikaciji hitro izloča iz krvi, njegov plazemski očistek je pri mačkah CL 0,44 l/kg/h in pri psih 0,81 l/kg/h, razpolovni čas t1/2 1,1 h pri mačkah in 0,8 h pri psih.
After intravenous administration, the terminal half-life of peginterferon alfa- 2a in healthy subjects is approximately 60 to 80 hours compared to values of 3-4 hours for standard interferon.
Po intravenskem dajanju je končna razpolovna doba peginterferona alfa-2a pri zdravih ljudeh približno 60 do 80 ur v primerjavi s 3 do 4 urami pri standardnem interferonu.
After intravenous bolus administration of somatropin, the mean terminal half-life t½ or t½ is about 20 minutes and the mean clearance is reported to be in the range of 116 - 174 ml/h/kg.
Po intravenski bolusni aplikaciji somatropina je povprečni končni razpolovni čas t½ oz. t½ približno 20 minut, povprečni očistek pa od 116 - 174 ml/uro/kg.
After intravenous bolus injection a radioactivity concentration of 2-3% injected dose/L is achieved in arterial plasma 10 minutes after injection.
10 minut po injiciranju z bolusno intravensko injekcijo doseže koncentracija radioaktivnih snovi vrednost 2–3 % injiciranega odmerka/l v arterijski plazmi.
After it has been dissolved in the supplied water for injections, the product should be clear.
Potem ko se je zdravilo raztopilo v priloženi vodi za injekcije, mora biti zdravilo bistro.
After its first use, the pen may be stored for a maximum of 4 weeks not above 30°C. Do not refrigerate.
Po prvi uporabi lahko peresnik shranjujete največ 4 tedne pri temperaturi do 30°C. Ne shranjujte v hladilniku.
After its first use, the product may be stored for a maximum of 4 weeks below 25°C. Do not refrigerate.
Po prvi uporabi lahko zdravilo shranjujete največ 4 tedne pri temperaturi do 25 °C. Ne shranjujte v hladilniku.
After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2-232 days).
Po zdravljenju z i.v. obliko vorikonazola je bila mediana trajanja zdravljenja s peroralno obliko zdravila 76 dni (območje 2-232 dni).
After knee replacement surgery, 10% of the patients receiving Xarelto had blood clots or died (79 out of 824), compared with 19% of the patients receiving enoxaparin (166 out of 878).
Po kirurški zamenjavi kolena je imelo 10 % bolnikov, ki so jemali zdravilo Xarelto, krvne strdke ali so umrli (79 bolnikov od 824) v primerjavi z 19 % bolnikov, ki so jemali enoksaparin (166 bolnikov od 878).
After labelling with the radioactive sodium pertechnetate (99mTc) solution for injection, radiolabelled NeoSpect will be injected before the scan is taken.
Po označevanju z raztopino radioaktivnega natrijevega pertehnetata (99mTc) za injiciranje, vam bodo injicirali radioaktivno označen NeoSpect pred slikanjem.
After Lucentis treatment you may experience some temporary vision blurring.
Po zdravljenju z zdravilom Lucentis lahko pride do začasne zameglitve vida.
After matching the dose size of the vaccine with the solvent size, quickly remove the exact number of ampoules needed from the liquid nitrogen container.
Po izbiri ustrezne količine topila glede na velikost odmerka cepiva, iz posode s tekočim dušikom hitro odstranite točno potrebno število ampul.
After miscarriage or abortion after 20 weeks of pregnancy
Po spontanem ali umetnem splavu po 20. tednom nosečnosti
After miscarriage or abortion before 20 weeks of pregnancy
Po spontanem ali umetnem splavu pred 20. tednom nosečnosti
After mixing Betaferon, you should administer the injection immediately (if Betaferon is not used immediately, see section 5. ‘How to store Betaferon’).
Ko pripravite zdravilo Betaferon, si ga morate takoj injicirati (če zdravila Betaferon ne uporabite takoj, glejte poglavje 5, Shranjevanje zdravila Betaferon).
After mixing Betaferon, you should give the injection immediately (if Betaferon is not used immediately, see section 5. ‘How to store Betaferon’ in the first part of this leaflet).
Ko pripravite zdravilo Betaferon, si ga morate takoj injicirati (če zdravila Betaferon ne uporabite takoj, glejte poglavje 5, Shranjevanje zdravila Betaferon v prvem delu tega navodila za uporabo).
After mixing HUMENZA should be stored in a refrigerator (2°C-8°C) (never place in the freezer) and should be used within 24 hours.
5 Po mešanju shranjujte cepivo HUMENZA v hladilniku (2 °C–8 °C) (nikoli ne zamrznite) in ga porabite v 24 urah.
After mixing HUMENZA should be stored in a refrigerator (2°C-8°C) (never place in the freezer) and should be used within 24 hours.
Po mešanju shranjujte cepivo HUMENZA v hladilniku (2 °C–8 °C) (nikoli ne zamrznite) in ga porabite v 24 urah.
After mixing the content of antigen vial into the adjuvant vial, HUMENZA is an emulsion for injection in a multidose vial containing 10 doses of 0.5 ml.
Po vmešanju vsebine viale z antigenom v vialo z adjuvansom je cepivo HUMENZA emulzija za injiciranje v večodmerni viali, ki vsebuje 10 odmerkov po 0,5 ml.
After mixing the oral powder with food or drinks, it may be stored at room temperature (not above 30oC) for up to 1 hour.
Ko peroralni prašek zmešate s hrano ali napitkom, lahko mešanico shranite pri sobni temperaturi (do 30 °C) za največ 1 uro.
After mixing with adjuvant emulsion: 10 doses of 0.5 ml)
Po premešanju z emulzijo adjuvansa: 10 odmerkov po 0,5 ml.
After mixing with Tc, the final product must be disposed of as radioactive waste in accordance with local law.
Po mešanju s tehnecijem mora biti končni produkt odstranjen kakor radioaktivni odpadek v skladu z lokalnimi predpisi.
After mixing with the antigen: 10 doses of 0.5 ml
Po premešanju z antigenom: 10 odmerkov po 0,5 ml
After mixing, 1 dose (0.5ml) contains:
Po premešanju 1 odmerek (0,5 ml) vsebuje:
After mixing, connect the bag to a high-speed, automated or semi-automated injection system.
Po mešanju povežite vrečko z avtomatskim ali pol- avtomatskim hitrim sistemom za injiciranje.
After mixing, HUMENZA should be stored in a refrigerator (2°C-8°C) and should be used within 24 hours.
Po premešanju morate cepivo HUMENZA hraniti v hladilniku (2 °C–8 °C) in uporabiti v 24 urah.
After mixing, Insulin Human Winthrop Basal is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Basal enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 15 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Comb 15 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 15 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insulin Human Winthrop Comb 15 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 15 is a uniformly milky-fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Comb 15 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 25 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Comb 25 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 25 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insulin Human Winthrop Comb 25 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 30 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Comb 30 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 30is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insulin Human Winthrop Comb 30 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešamju je Insulin Human Winthrop Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insulin Human Winthrop Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insulin Human Winthrop Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insulin Human Winthrop Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Basal is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insuman Basal enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Basal is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insuman Basal enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 15 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insuman Comb 15 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 15 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insuman Comb 15 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 25 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insuman Comb 25 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 25 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insuman Comb 25 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 30 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je Insuman Comb 30 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 30 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešanju je zdravilo Insuman Comb 30 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.
After mixing, Insuman Comb 50 is a uniformly milky fluid (suspension for injection), with no clumps, particles or flocculation visible.
Po mešamju je Insuman Comb 50 enakomerno mlečna tekočina (suspenzija za injiciranje) brez grud, delcev ali vidnih kosmov.